News, musings and commentary on pharmaceutical law issues, technology, and litigation.
No advice, though.
Lawyers for consumers and injured people.(No advice on this blog, though) TOLL FREE 855-525-3955
Tuesday, August 23, 2011
Analysis Continues of Fallout From FDA's SSRI Warning
From Psychiatry Online:
The “black box” warning on antidepressants appears to have affected the likelihood of making an outpatient visit for depression, but not of receiving an antidepressant prescription following a diagnosis of depression.
The number of children's outpatient office visits for depression and visits during which an antidepressant was prescribed dropped in the wake of the 2003 U.S. Food and Drug Administration (FDA) advisory linking an increased risk of suicidality with antidepressant use among pediatric patients.
Yet children diagnosed with depression appeared no less likely to be prescribed antidepressants than before the warning, according to an analysis appearing in the July Psychiatric Services.